Abstract 12677: Serum FGF23 Level is Associated With Cardiac Abnormality Among Patients Without Chronic Kidney Disease Stages
Background: Several experimental studies have demonstrated that fibroblast growth factor 23 (FGF23) may induce myocardial hypertrophy. On the other hand, few studies have clearly demonstrated the relationship between FGF23 level and left ventricular hypertrophy among subjects without chronic kidney disease (CKD; i.e., CKD stage G1 or G2). We investigate the association between FGF23 and cardiac parameters among 903 patients with various degrees of renal function, including 234 patients with CKD stage G1/G2.
Methods and Results: Serum levels of full-length FGF23 were determined by enzyme immunoassay. After adjustment for sex, age, and estimated glomerular filtration rate (eGFR), the highest FGF23 tertile was significantly associated with left ventricular hypertrophy among patients with CKD stage G1/G2 as compared with the lowest FGF23 tertile as well as among those with CKD stage G3a/G3b/G4. This association retained significance after further adjustment for serum levels of corrected calcium, inorganic phosphate, and C-reactive protein. FGF23 was also associated with left ventricular ejection fraction (LVEF) <50% among patients with CKD stage G1/G after multivariate analysis. By the ROC curve analysis among these no-CKD patients, compared with model 1 (combination of age, sex, and eGFR), area under the curve of model 2 (model 1+FGF23) was significantly greater for the prediction of left ventricular hypertrophy.
Conclusions: An association between FGF23 and cardiac hypertrophy and systolic dysfunction was observed among patients without CKD as well as those with CKD, suggesting FGF23 per se may have direct effect on the cardiac geometry and performance.
Author Disclosures: S. Tanaka: None. H. Morita: None. Y. Takeda: None. S. Fujita: None. K. Sohmiya: None. M. Hoshiga: None. N. Ishizaka: None.
- © 2016 by American Heart Association, Inc.